BMT CTN Protocol 0804

Phase II Study of Reduced- Intensity Allogeneic Stem Cell Transplant For High Risk Chronic Lymphocytic Leukemia (CLL)

Below are protocol-related documents, which may be periodically updated.

            Protocol Chair: Richard T. Maziarz, MD (503-494-4606)

            Protocol Officer: Mary Horowitz, MD

            Alliance Regulatory Group:



This study has reached its final accrual goal; the study closed to new patient accrual on January 27, 2014.